You are here:
Alecensa
Alecensa as monotherapy is indicated as adjuvant treatment following complete tumour resection for adult patients with ALK‑positive NSCLC at high risk of recurrence
No estimate possible yet
3,887,700.00
Positive CHMP opinion
Alectinib
Oncology
Indication extension
Lung cancer
Roche
Tyrosine kinase inhibitor
Oral
Capsule
Intermural (MSZ)
Centralised (EMA)
Normal trajectory
No
November 2023
June 2024
Positieve CHMP-opinie april 2024
Chemotherapie
Maximal 23.9 month / months
2 times a day
600mg
https://www.ema.europa.eu/en/documents/product-information/alecensa-epar-product-information_nl.pdf https://classic.clinicaltrials.gov/ct2/show/NCT03456076
36 - 84
Market share is generally not included unless otherwise stated.
https://www.zorginstituutnederland.nl/publicaties/adviezen/2021/11/15/pakketadvies-osimertinib-tagrisso-bij-niet-kleincellige-longkanker-nsclc https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9020874/
Volgens de budget impact analyse van osimertinib in de adjuvante NSCLC indicatie doen zich jaarlijks 1.193 stadium IB-IIIA gereseceerd NSCLC patiënten voor. Hiervan heeft minimaal 3% en maximaal 7% een ALK mutatie. Het jaarlijks patiëntvolume komt hiermee op minimaal 36 en max 84.
64,795.00
Z-index en SMPC Alecensa
Volgens de Z-index bedraagt de prijs voor Alecensa 150mg 240 stuks €5.399,64. De dosering is 600mg 2x daags. Hiermee komen de jaarlijkse kosten op €64.795,68 per patiënt.
This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year.
There is currently nothing known about off label use.
There is currently nothing known about indication extensions.
There is currently no futher information available.
Understanding of expected market entry of innovative medicines